Intriguingly, tumor-derived S100A9—released as a DAMP—likely interacts with RAGE and TLR4 on both cancer and stromal cells, triggering NF-κB and MAPK/ERK signaling cascades that promote a pro-inflammatory microenvironment, enhance tumor cell proliferation and facilitate pre-metastatic niche formation. Here, S100A9 is linked to cancer.